Tumor gene therapy made easy: Allogeneic major histocompatibility complex in the C6 rat glioma model

Andreas S Beutler, Michaela S. Banck, Dirk Wedekind, Hans J. Hedrich

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The C6 glioma in the immune-competent rat is a frequently used model in brain tumor gene therapy research. It displays the histologic hallmarks of the human glioblastoma and has been employed to demonstrate new mechanisms of anti-tumor immunity and therapeutic strategies. We noted that C6 tumors regressed spontaneously in three of five animals and that protective anti-tumor immunity ensued without therapeutic intervention. A review of the literature revealed that different rat strains are used as 'syngeneic' host for the C6 cell glioma, namely, BDIX, BDX, Sprague-Dawley, and Wistar. Allelotyping of the RT1.A (rat MHC I homolog) by a serologic technique and of the RT1.B (rat MHC II homolog) by a newly developed molecular technique showed that C6 cells express the haplotype RT1(u) and are allogeneic in the preceding rat strains. Expression of the gene encoding the transactivator CIITA in C6 gliomas using an EBV-based transduction system led to induction of MHC I and II and thereby mimicked therapeutic responses that could not operate in syngeneic models. These data suggest that the C6 glioma model in the immune-competent rat should no longer be used to study gene therapy strategies, that the available data obtained in this model need to be critically reinterpreted, and that findings obtained in the C6 glioma model may not be sufficient to support a clinical trial in glioblastoma patients.

Original languageEnglish (US)
Pages (from-to)95-101
Number of pages7
JournalHuman Gene Therapy
Volume10
Issue number1
DOIs
StatePublished - Jan 1 1999
Externally publishedYes

Fingerprint

Major Histocompatibility Complex
Glioma
Genetic Therapy
Neoplasms
Glioblastoma
Immunity
Trans-Activators
Human Herpesvirus 4
Brain Neoplasms
Haplotypes
Therapeutics
Clinical Trials
Gene Expression
Research

ASJC Scopus subject areas

  • Genetics

Cite this

Tumor gene therapy made easy : Allogeneic major histocompatibility complex in the C6 rat glioma model. / Beutler, Andreas S; Banck, Michaela S.; Wedekind, Dirk; Hedrich, Hans J.

In: Human Gene Therapy, Vol. 10, No. 1, 01.01.1999, p. 95-101.

Research output: Contribution to journalArticle

Beutler, Andreas S ; Banck, Michaela S. ; Wedekind, Dirk ; Hedrich, Hans J. / Tumor gene therapy made easy : Allogeneic major histocompatibility complex in the C6 rat glioma model. In: Human Gene Therapy. 1999 ; Vol. 10, No. 1. pp. 95-101.
@article{696a2a0683b64dfcadbaae93f2ad23d4,
title = "Tumor gene therapy made easy: Allogeneic major histocompatibility complex in the C6 rat glioma model",
abstract = "The C6 glioma in the immune-competent rat is a frequently used model in brain tumor gene therapy research. It displays the histologic hallmarks of the human glioblastoma and has been employed to demonstrate new mechanisms of anti-tumor immunity and therapeutic strategies. We noted that C6 tumors regressed spontaneously in three of five animals and that protective anti-tumor immunity ensued without therapeutic intervention. A review of the literature revealed that different rat strains are used as 'syngeneic' host for the C6 cell glioma, namely, BDIX, BDX, Sprague-Dawley, and Wistar. Allelotyping of the RT1.A (rat MHC I homolog) by a serologic technique and of the RT1.B (rat MHC II homolog) by a newly developed molecular technique showed that C6 cells express the haplotype RT1(u) and are allogeneic in the preceding rat strains. Expression of the gene encoding the transactivator CIITA in C6 gliomas using an EBV-based transduction system led to induction of MHC I and II and thereby mimicked therapeutic responses that could not operate in syngeneic models. These data suggest that the C6 glioma model in the immune-competent rat should no longer be used to study gene therapy strategies, that the available data obtained in this model need to be critically reinterpreted, and that findings obtained in the C6 glioma model may not be sufficient to support a clinical trial in glioblastoma patients.",
author = "Beutler, {Andreas S} and Banck, {Michaela S.} and Dirk Wedekind and Hedrich, {Hans J.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1089/10430349950019228",
language = "English (US)",
volume = "10",
pages = "95--101",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Tumor gene therapy made easy

T2 - Allogeneic major histocompatibility complex in the C6 rat glioma model

AU - Beutler, Andreas S

AU - Banck, Michaela S.

AU - Wedekind, Dirk

AU - Hedrich, Hans J.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - The C6 glioma in the immune-competent rat is a frequently used model in brain tumor gene therapy research. It displays the histologic hallmarks of the human glioblastoma and has been employed to demonstrate new mechanisms of anti-tumor immunity and therapeutic strategies. We noted that C6 tumors regressed spontaneously in three of five animals and that protective anti-tumor immunity ensued without therapeutic intervention. A review of the literature revealed that different rat strains are used as 'syngeneic' host for the C6 cell glioma, namely, BDIX, BDX, Sprague-Dawley, and Wistar. Allelotyping of the RT1.A (rat MHC I homolog) by a serologic technique and of the RT1.B (rat MHC II homolog) by a newly developed molecular technique showed that C6 cells express the haplotype RT1(u) and are allogeneic in the preceding rat strains. Expression of the gene encoding the transactivator CIITA in C6 gliomas using an EBV-based transduction system led to induction of MHC I and II and thereby mimicked therapeutic responses that could not operate in syngeneic models. These data suggest that the C6 glioma model in the immune-competent rat should no longer be used to study gene therapy strategies, that the available data obtained in this model need to be critically reinterpreted, and that findings obtained in the C6 glioma model may not be sufficient to support a clinical trial in glioblastoma patients.

AB - The C6 glioma in the immune-competent rat is a frequently used model in brain tumor gene therapy research. It displays the histologic hallmarks of the human glioblastoma and has been employed to demonstrate new mechanisms of anti-tumor immunity and therapeutic strategies. We noted that C6 tumors regressed spontaneously in three of five animals and that protective anti-tumor immunity ensued without therapeutic intervention. A review of the literature revealed that different rat strains are used as 'syngeneic' host for the C6 cell glioma, namely, BDIX, BDX, Sprague-Dawley, and Wistar. Allelotyping of the RT1.A (rat MHC I homolog) by a serologic technique and of the RT1.B (rat MHC II homolog) by a newly developed molecular technique showed that C6 cells express the haplotype RT1(u) and are allogeneic in the preceding rat strains. Expression of the gene encoding the transactivator CIITA in C6 gliomas using an EBV-based transduction system led to induction of MHC I and II and thereby mimicked therapeutic responses that could not operate in syngeneic models. These data suggest that the C6 glioma model in the immune-competent rat should no longer be used to study gene therapy strategies, that the available data obtained in this model need to be critically reinterpreted, and that findings obtained in the C6 glioma model may not be sufficient to support a clinical trial in glioblastoma patients.

UR - http://www.scopus.com/inward/record.url?scp=0032927487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032927487&partnerID=8YFLogxK

U2 - 10.1089/10430349950019228

DO - 10.1089/10430349950019228

M3 - Article

C2 - 10022534

AN - SCOPUS:0032927487

VL - 10

SP - 95

EP - 101

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 1

ER -